Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Sajic, Marija ^a   Hunt, David P J ^a,b,d   Lee, Woojin ^a   Compston, D Alastair S ^b   Schweimer, Judith V ^c   Gregson, Norman A ^a   Chandran, Siddharthan ^d   Smith, Kenneth J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BRAIN ELECTROPHYSIOLOGY; CD4+ T LYMPHOCYTE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; GUILLAIN BARRE SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL TRANSPLANTATION; NERVE CELL INHIBITION; NEURITIS; NONHUMAN; OUTCOME ASSESSMENT; RAT; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; ANIMAL; CELL PROLIFERATION; CYTOLOGY; LEWIS RAT; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT OUTCOME;

RATTUS;

ANIMALS; CELL PROLIFERATION; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL TRANSPLANTATION; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; RATS; RATS, INBRED LEW; T-LYMPHOCYTES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84863171061     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030708     Document Type: Article

References (21)

1. Gerdoni E, Gallo B, Casazza S, Musio S, Bonanni I, et al. (2007) Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 61: 219-227.
2. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, et al. (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106: 1755-1761.
3. Martino G, Franklin RJ, Van Evercooren AB, Kerr DA, (2010) Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat Rev Neurol 6: 247-255.
4. Freedman MS, Bar-Or A, Atkins HL, Karussis D, Frassoni F, et al. (2010) The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler 16: 503-510.
5. Einstein O, Fainstein N, Vaknin I, et al. (2007) Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression. Ann Neurol 61: 209-218.
6. Bechtold DA, Yue X, Evans RM, Davies M, Gregson NA, et al. (2005) Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide Brain 128: 18-28.
7. Hughes RA, Allen D, Makowska A, Gregson NA, (2006) Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 11: 30-46.
8. Hunt DPJ, Webber D, Irvine KA, Blakemore B, Compston, DAS, et al. (2008) Effects of direct injection of bone marrow-derived mesenchymal stromal cells into the demyelinated spinal cord. Cell Transplantation 17: 865-873.
9. Hunt DPJ, Sajic M, Compston DAS, Smith K, Chandran S, (2010) Origins of gliogenic precursors in adult skin and bone marrow. Stem Cells Dev Jul;19 (7): 1055-65.
10. Sajic M, Gregson N, Hughes RA, Smith K, (2011) The role of CD8+ cells in a model of MS induced with rMOG. Mult Scler Sep 30.
11. Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, et al. (2009) IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 119: 2052-2061.
12. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, et al. (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371: 1579-1586.
13. Lazarus HM, Koc ON, Devine SM, et al. (2005) Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 11: 389-398.
14. Tyndall A, Uccelli A, (2009) Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Bone Marrow Transplant 43: 821-828.
15. Uccelli A, Moretta L, Pistoia V, (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8: 726-736.
16. Uccelli A, Mancardi G, Chiesa S, (2008) Is there a role for mesenchymal stem cells in autoimmune diseases? Autoimmunity 41: 592-595.
17. Jones S, Horwood N, Cope A, Dazzi F, (2007) The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol 179 (5): 2824-2831.
18. Pluchino S, Zanotti L, Rossi B, Brambilla E, Ottoboni L, et al. (2005) Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature Jul 14;436 (7048): 266-7.
19. Hadden RD, Gregson N, Gold R, Smith K, Hughes RA, (2002) Accumulation of immunoglobulin across the 'blood-nerve barrier' in spinal roots in adoptive transfer experimental autoimmune neuritis. Neuropathol Appl Neurobiol Dec;28 (6): 489-97.
20. Maurer M, Tokya KV, Gold R, (2002) Immune mechanisms in acquired demyelinating neuropathies: lessons from animal models. Neuromuscul Disord May;12 (4): 405-14.
21. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, et al. (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103 (12): 4619-4621.